New York, USA, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Tendinopathy Market to Register Incremental Growth During the Study Period (2019–2032), Estimates DelveInsight | Leading Companies in the Market - Novartis, SynOx, Abbisko, AmMax, Deciphera
The incidence of tendinopathy has been rising in recent years, and common explanations are the increasing age of society and the overall rise in extreme and overuse sports. There have been significant advancements in the field of tendinopathy market. Various organizations and research institutes are undertaking research activities to discover successful tendinopathy treatments.
DelveInsight’s Tendinopathy Market Insights report includes a comprehensive understanding of current treatment practices, tendinopathy emerging drugs, market share of individual therapies, and current and forecasted tendinopathy market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Tendinopathy Market Report
- As per DelveInsight’s analysis, the tendinopathy market is anticipated to grow at a significant CAGR by 2032.
- According to DelveInsight’s analysis, tendinopathy incidence in the United States has shown an increasing trend. As per the estimates, the United States accounted for ~12 million incident cases in 2022.
- Leading tendinopathy companies such as Novartis, SynOx Therapeutics Limited, Abbisko Therapeutics Co, Ltd, AmMax Bio, Inc., Deciphera Pharmaceuticals LLC, and others are developing novel tendinopathy drugs that can be available in the tendinopathy market in the coming years.
- Some of the key therapies for tendinopathy treatment include NGI226, Emactuzumab, ABSK021, AMB-05X, DCC-3014, AIN457, and others.
Discover which therapies are expected to grab the tendinopathy market share @ Tendinopathy Market Report
Tendinopathy Overview
Tendinopathy represents a compromised healing process within the tendon, marked by the chaotic growth of tenocytes, irregularities within tenocyte cells, the disruption of collagen fibers, and a subsequent rise in the non-collagenous matrix. Tendinopathy is a broad term used to describe clinical conditions associated with overuse in and around tendons, encompassing both pain and pathological characteristics. Common overuse tendinopathies affect tendons such as the rotator cuff, medial and lateral elbow epicondyles, patellar tendon, gluteal tendons, and the Achilles tendon. The identification of tendinopathy relies on clinical indicators and the patient's historical record of localized tendon pain and stiffness triggered by activity. A comprehensive clinical assessment, confirming the patient's reported history of load-induced tendon discomfort through a physical examination, is pivotal in making a diagnosis.
Tendinopathy Epidemiology Segmentation
The tendinopathy epidemiology section provides insights into the historical and current tendinopathy patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
The tendinopathy market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Incident Cases of Tendinopathy
- Gender-specific Incident Cases of Tendinopathy
- Type-specific Incident Cases of Tendinopathy
- Region-specific Incident Cases of Tendinopathy
- Total Treated Cases of Tendinopathy
Download the report to understand which factors are driving tendinopathy epidemiology trends @ Tendinopathy Epidemiological Insights
Tendinopathy Treatment Market
The primary objectives of tendinopathy treatment involve alleviating symptoms, particularly pain, facilitating tendon recovery, and enhancing patient functionality. A variety of therapeutic options are available, such as rest, cold therapy, eccentric exercises, nutraceuticals, ultrasound therapy, sclerosing injections, extracorporeal shockwave therapy, splinting, taping, cryotherapy, electrotherapy, glyceryl trinitrate patches, nonsteroidal anti-inflammatory drugs (NSAIDs), and peritendinous injections. Surgical intervention is typically considered a last resort for persistent tendinopathy cases after exploring all non-operative alternatives. Nevertheless, conservative measures remain the cornerstone of treatment for most tendinopathies.
At present, exercise routines, known as tendon loading programs, stand as the most effective non-invasive method for managing tendinopathy. These exercises have demonstrated positive outcomes among individuals with chronic Achilles tendinopathy and patellar tendinopathy. Regarding medication, NSAIDs play a role in managing tendinopathy-related pain. Prostaglandins, compounds derived from arachidonic acid, contribute to acute inflammation development. Both oral and topical NSAIDs effectively alleviate the short-term pain associated with this condition. Additionally, corticosteroids are sometimes administered via injections around the affected tendon to alleviate tendinitis. Cortisone, a type of naturally occurring corticosteroid, reduces inflammation and provides pain relief.
Platelet-rich plasma (PRP) stands as an established therapeutic approach for tendinopathy. This method involves drawing a blood sample, centrifuging it to isolate platelets and therapeutic elements, and then administering the resulting solution via injection into the area affected by persistent tendon irritation. Complementing this, physical therapy proves advantageous, employing tailored exercises to both stretch and fortify the impacted muscle-tendon ensemble. Additionally, topical glyceryl trinitrate is recognized as a safe and effective treatment or supplement for managing tendinopathy. Nonetheless, its usage might correlate with a higher likelihood of headaches.
Learn more about the FDA-approved drugs for tendinopathy @ Drugs for Tendinopathy Treatment
Key Tendinopathy Therapies and Companies
- NGI226: Novartis
- Emactuzumab: SynOx Therapeutics Limited
- ABSK021: Abbisko Therapeutics Co, Ltd
- AMB-05X: AmMax Bio, Inc.
- DCC-3014: Deciphera Pharmaceuticals LLC
- AIN457: Novartis
To know more about tendinopathy clinical trials, visit @ Tendinopathy Treatment Drugs
The tendinopathy market dynamics are anticipated to change in the coming years. Preclinical models have given credence to this emerging therapeutic modality, and compared to scaffolds and growth factors, there is a paucity of clinical studies using stem cells for augmentation of tendon repair or for treating tendinopathy. Gene therapy is a promising method for facilitating the trafficking of growth factors to the injured site, potentially allowing sustained temporal delivery, while novel mini-invasive procedures that target underlying pathology, such as abnormal neoinnervation, are being developed and are initially promising.
Furthermore, many potential therapies are being investigated for the treatment of tendinopathy, and it is safe to predict that the treatment space will significantly impact the tendinopathy market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the tendinopathy market in the 7MM.
However, several factors may impede the growth of the Tendinopathy market. The lack of understanding of the pathophysiology and clinical relevance may represent a missed opportunity to make the correct diagnosis, potentially leading to a delayed diagnosis and misdiagnosis. Despite a myriad of clinical advances in treating tendinopathies, there remains an unmet need for effective therapeutic strategies to augment intrinsic and/or surgical repair. Already available off-labeled drugs might offer tough competition to emerging ones. The communication gap between doctors and patients is one of the primary reasons for unsatisfactory patient care currently and might hinder the growth of the tendinopathy market and access to medications.
Moreover, tendinopathy treatment poses a significant economic burden and disrupts patients’ overall well-being and QOL. Furthermore, the tendinopathy market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the tendinopathy market growth.
| Tendinopathy Report Metrics | Details |
| Study Period | 2019–2032 |
| Tendinopathy Report Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
| Key Tendinopathy Companies | Novartis, SynOx Therapeutics Limited, Abbisko Therapeutics Co, Ltd, AmMax Bio, Inc., Deciphera Pharmaceuticals LLC, and others |
| Key Tendinopathy Therapies | NGI226, Emactuzumab, ABSK021, AMB-05X, DCC-3014, AIN457, and others |
Scope of the Tendinopathy Market Report
- Tendinopathy Therapeutic Assessment: Tendinopathy current marketed and emerging therapies
- Tendinopathy Market Dynamics: Attribute Analysis of Emerging Tendinopathy Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Tendinopathy Market Access and Reimbursement
Discover more about tendinopathy drugs in development @ Tendinopathy Clinical Trials
Table of Contents
| 1. | Tendinopathy Market Key Insights |
| 2. | Tendinopathy Market Report Introduction |
| 3. | Tendinopathy Market Overview at a Glance |
| 4. | Tendinopathy Market Executive Summary |
| 5. | Disease Background and Overview |
| 6. | Tendinopathy Treatment and Management |
| 7. | Tendinopathy Epidemiology and Patient Population |
| 8. | Patient Journey |
| 9. | Tendinopathy Marketed Drugs |
| 10. | Tendinopathy Emerging Drugs |
| 11. | Seven Major Tendinopathy Market Analysis |
| 12. | Tendinopathy Market Outlook |
| 13. | Potential of Current and Emerging Therapies |
| 14. | KOL Views |
| 15. | Unmet Needs |
| 16. | SWOT Analysis |
| 17. | Appendix |
| 18. | DelveInsight Capabilities |
| 19. | Disclaimer |
| 20. | About DelveInsight |
Related Reports
Tendinopathy Epidemiology Forecast
Tendinopathy Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted Tendinopathy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Tendinopathy Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key tendinopathy companies, including MiMedx, Hisamitsu Pharmaceuticals, Seikagaku Corporation, MetrioPharm, among others.
Tenosynovitis Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key tenosynovitis companies including Bayer AG, Pfizer Inc., Sanofi, Zyla Life Sciences, Novartis AG, Johnson & Johnson Services, Inc, Merch & Co., Inc, Eli Lilly and Company, Abbott, ABIOGEN PHARMA S.p.A., and Ampio Pharmaceuticals Inc, among others.
Tennis Elbow Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key tennis elbow companies, including DJO Global, Inc., Beurer GmbH, 3M, AKSIGEN, BTL Corporate, Johari Digit, Ossur Corporate, OttoBock HealthCare, Veritas Health, Zimmer Biomet, among others.
Tennis Elbow Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted tennis elbow epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect with us on LinkedIn|Facebook|Twitter
